Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909415 | 0.88 | RORC (0.37) | PTGS2PTGS1ABCG2 | |
| SCHEMBL30961017 | 0.85 | ABCG2 (0.34) | ABCG2 | |
| SCHEMBL29909083 | 0.84 | ABCG2 (0.33) | ABCG2 | |
| SCHEMBL29909909 | 0.83 | DHODH (0.41) | PTGS2PTGS1ABCG2 | |
| SCHEMBL29909607 | 0.80 | ABCG2 (0.34) | PTGS2PTGS1ABCG2 | |
| SCHEMBL29909707 | 0.80 | ABCG2 (0.36) | ABCG2 | |
| SCHEMBL29909927 | 0.79 | RORC (0.38) | PTGS2PTGS1CYP2C19CYP2C9KDM1A | |
| SCHEMBL29909330 | 0.79 | CYP1A2 (0.38) | CYP2C19CYP2C9ABCG2 | |
| SCHEMBL29909745 | 0.79 | PTGS2 (0.36) | PTGS2PTGS1KDM1A | |
| SCHEMBL23601322 | 0.79 | PTGS2 (0.38) | PTGDR2PTGS2PTGS1CYP2C8CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PTGDR2 837/4885PTGS2 1810/4885PTGS1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.